Furthermore, in Aβ immunotherapy ApoE4 positivity increases the incidence of amyloid related imaging abnormalities (ARIA), a treatment-limiting adverse event related to cerebral amyloid angiopathy and microvascular dysfunction 23–25, highlighting the negative neurovascular impact of ApoE4. The gene discussed is APOE; the disease is amyloidosis.